Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome (II) vs Etoposide with Adebrelimab and Carboplatin in ES-SCLC
NCT06739928Phase 2Recruiting
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan liposome in small cell lung cancer (SCLC) (2 arms), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoint: 1-year Overall Survival Rate. Started Jan 2025; status: recruiting.
02
Drugs
irinotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06739928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739928.